Stem cell therapy for central nervous system injury 4 and longterm antibiotic therapy for chronic Lyme disease can result in serious adverse events.
5
From November 14 to December 11, 2017, we identified all existing campaigns posted since November 1, 2015, in the United States and Canada by searching for terms related to each treatment. Only campaigns with evidence that the fundraisers intended to direct all or some of the raised funds to the targeted treatment for an individual were included. The number of campaigns and the funds sought and raised for each treatment were tabulated. We collected any specific practitioner names and treatment destinations to contextualize our analysis.
Results | Of the 1636 campaigns identified, 1059 mentioned intention to direct funds to 1 of the 5 treatments, seeking a total of $27 249 487.99 ( We identified 9 named practitioners and 8 countries that campaigners intended to visit, including clinics in Germany and Mexico for homeopathic or naturopathic cancer treatments, a New Orleans clinic offering HBOT for brain injury, and clinics in the United States, Panama, Thailand, India, China, and Mexico for stem cell therapies.
Discussion | More than 1000 medical crowdfunding campaigns for 5 treatments that are unsupported by evidence or potentially unsafe raised more than $6.7 million. Another study found that 408 campaigns raised more than $1 million for unproven stem cell interventions. 6 The present study included a broader set of treatments and suggests that medical crowdfunding is being used for multiple problematic treatments. These results reveal that a wide scope of campaigns for unsupported, ineffective, or potentially dangerous treatments are moderately successful in obtaining funding. Assuming that the funds raised are spent to pay for these treatments, donors indirectly contributed millions of dollars to practitioners to deliver dubious, possibly unsafe care. This study has limitations. Only 5 treatments and 4 platforms were analyzed. These were selected because of clinical experience and visibility. Whether the results generalize is unknown. Native search engines vary in quality; an external search engine may have yielded more results. Despite expressed intent, campaigners may not have used funds on specified treatments. 2018;319(18):1935-1936. doi:10.1001/jama.2018 The licensee is responsible for securing a collaborative practice agreement, which requires a 30-day period treating patients with the collaborating physician. Subsequently, assistant physicians can practice within 50 miles and with review of 10% of all charts. The collaborating physician must be immediately available for consultation electronically or in person.
There is no time limit on practice as an assistant physician or in obtaining a collaborative agreement once licensed. Arkansas, Kansas, and Utah have enacted similar but more restrictive legislation, and other states have considered doing the same. We describe the cohort of licensees from the first year of this novel license in Missouri.
